Astera Labs Inc (ALAB) concluded trading on Thursday at a closing price of $58.86, with 3.99 million shares of worth about $235.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.14% during that period and on April 10, 2025 the price saw a loss of about -8.50%. Currently the company’s common shares owned by public are about 162.02M shares, out of which, 121.92M shares are available for trading.
Stock saw a price change of 5.71% in past 5 days and over the past one month there was a price change of -14.47%. Year-to-date (YTD), ALAB shares are showing a performance of -55.56% which decreased to -13.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $36.22 but also hit the highest price of $147.39 during that period. The average intraday trading volume for Astera Labs Inc shares is 5.23 million. The stock is currently trading -8.39% below its 20-day simple moving average (SMA20), while that difference is down -22.66% for SMA50 and it goes to -22.85% lower than SMA200.
Astera Labs Inc (NASDAQ: ALAB) currently have 162.02M outstanding shares and institutions hold larger chunk of about 58.32% of that.
The stock has a current market capitalization of $9.54B and its 3Y-monthly beta is at 0.25. It has posted earnings per share of -$0.54 in the same period. It has Quick Ratio of 11.21 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALAB, volatility over the week remained 17.33% while standing at 9.01% over the month.
Stock’s fiscal year EPS is expected to rise by 50.07% while it is estimated to increase by 36.22% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on March 14, 2025 offering an Outperform rating for the stock and assigned a target price of $82 to it. Coverage by Northland Capital stated Astera Labs Inc (ALAB) stock as an Outperform in their note to investors on January 28, 2025, suggesting a price target of $120 for the stock. On January 21, 2025, Morgan Stanley Downgrade their recommendations, while on January 02, 2025, Northland Capital Downgrade their ratings for the stock with a price target of $120. Stock get a Buy rating from Citigroup on November 18, 2024.
